316 related articles for article (PubMed ID: 27324616)
1. Human leucocyte antigen class I-redirected anti-tumour CD4
Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
[TBL] [Abstract][Full Text] [Related]
2. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
3. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
4. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
[TBL] [Abstract][Full Text] [Related]
5. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
[TBL] [Abstract][Full Text] [Related]
6. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
7. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
8. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
9. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
[TBL] [Abstract][Full Text] [Related]
10. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
Voelkl S; Moore TV; Rehli M; Nishimura MI; Mackensen A; Fischer K
Cancer Immunol Immunother; 2009 May; 58(5):709-18. PubMed ID: 18836718
[TBL] [Abstract][Full Text] [Related]
11. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract][Full Text] [Related]
12. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
[TBL] [Abstract][Full Text] [Related]
13. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.
Zeng G; Li Y; El-Gamil M; Sidney J; Sette A; Wang RF; Rosenberg SA; Robbins PF
Cancer Res; 2002 Jul; 62(13):3630-5. PubMed ID: 12097265
[TBL] [Abstract][Full Text] [Related]
14. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
15. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
Engels B; Chervin AS; Sant AJ; Kranz DM; Schreiber H
Mol Ther; 2012 Mar; 20(3):652-60. PubMed ID: 22233579
[TBL] [Abstract][Full Text] [Related]
16. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
17. SHP-1 phosphatase activity counteracts increased T cell receptor affinity.
Hebeisen M; Baitsch L; Presotto D; Baumgaertner P; Romero P; Michielin O; Speiser DE; Rufer N
J Clin Invest; 2013 Mar; 123(3):1044-56. PubMed ID: 23391724
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.
Schmid DA; Irving MB; Posevitz V; Hebeisen M; Posevitz-Fejfar A; Sarria JC; Gomez-Eerland R; Thome M; Schumacher TN; Romero P; Speiser DE; Zoete V; Michielin O; Rufer N
J Immunol; 2010 May; 184(9):4936-46. PubMed ID: 20351194
[TBL] [Abstract][Full Text] [Related]
19. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
[TBL] [Abstract][Full Text] [Related]
20. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
